Stock listing
NASDAQ:BDTX Black Diamond Therapeutics, Inc. Stock
Home listing (NASDAQ) of Black Diamond Therapeutics, Inc.
Follow Black Diamond Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:BDTX
$1.31 USD -0.12 (-8.4%)
Close on Nov 20, 2026
- Day range
- $1.31 – $1.41 USDNov 20, 2026
- Volume
- 663,186 sharesNov 20, 2026
- Market cap
- $75.28M USDAt the close on Nov 20, 2026 · price × 57.47M shares outstanding
- 52-week range
- $1.31 – $3.97 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.32M USDMedian day 613,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BDTX · Home | $1.31 USD | -0.12 (-8.4%) | 663,186 | $1.33 | $1.41 | $1.31 | $1.43 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BDTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.31 | -0.12 | -8.4% | $1.33 | $1.41 | $1.31 | 663,186 | |
| $1.43 | -0.01 | -0.7% | $1.42 | $1.46 | $1.39 | 603,018 | |
| $1.44 | -0.09 | -5.9% | $1.50 | $1.529 | $1.391 | 645,967 | |
| $1.53 | +0.06 | +4.1% | $1.46 | $1.53 | $1.40 | 708,747 | |
| $1.47 | -0.05 | -3.3% | $1.55 | $1.57 | $1.45 | 896,661 | |
| $1.52 | -0.09 | -5.6% | $1.61 | $1.635 | $1.51 | 956,159 | |
| $1.61 | +0.015 | +0.9% | $1.68 | $1.689 | $1.58 | 852,310 | |
| $1.595 | -0.265 | -14.2% | $1.90 | $1.91 | $1.58 | 1,401,003 | |
| $1.86 | +0.125 | +7.2% | $1.76 | $1.905 | $1.745 | 730,430 | |
| $1.735 | +0.075 | +4.5% | $1.65 | $1.79 | $1.64 | 432,083 | |
| $1.66 | -0.24 | -12.6% | $1.89 | $1.90 | $1.65 | 562,281 | |
| $1.90 | +0.09 | +5.0% | $1.86 | $1.96 | $1.84 | 607,514 | |
| $1.81 | +0.06 | +3.4% | $1.76 | $1.85 | $1.76 | 331,799 | |
| $1.75 | -0.03 | -1.7% | $1.79 | $1.86 | $1.75 | 493,685 | |
| $1.78 | -0.08 | -4.3% | $1.86 | $1.90 | $1.76 | 515,418 | |
| $1.86 | +0.03 | +1.6% | $1.85 | $1.89 | $1.795 | 548,804 | |
| $1.83 | +0.08 | +4.6% | $1.74 | $1.87 | $1.705 | 1,043,391 | |
| $1.75 | +0.06 | +3.6% | $1.71 | $1.77 | $1.645 | 1,099,234 | |
| $1.69 | -0.19 | -10.1% | $1.90 | $1.90 | $1.67 | 861,132 | |
| $1.88 | -0.20 | -9.6% | $2.05 | $2.05 | $1.83 | 927,726 | |
| $2.08 | 0.00 | 0.0% | $2.06 | $2.105 | $2.03 | 790,955 | |
| $2.08 | +0.01 | +0.5% | $2.07 | $2.14 | $2.005 | 2,355,483 | |
| $2.07 | +0.26 | +14.4% | $1.82 | $2.14 | $1.82 | 2,113,789 | |
| $1.81 | +0.09 | +5.2% | $1.71 | $1.835 | $1.71 | 825,582 | |
| $1.72 | -0.02 | -1.1% | $1.75 | $1.75 | $1.675 | 539,800 | |
| $1.74 | +0.04 | +2.4% | $1.69 | $1.74 | $1.67 | 624,700 | |
| $1.70 | +0.02 | +1.2% | $1.67 | $1.76 | $1.63 | 1,069,400 | |
| $1.68 | -0.09 | -5.1% | $1.76 | $1.77 | $1.60 | 1,141,000 | |
| $1.77 | -0.06 | -3.3% | $1.865 | $1.865 | $1.765 | 377,700 | |
| $1.83 | +0.02 | +1.1% | $1.81 | $1.83 | $1.79 | 448,800 | |
| $1.81 | -0.02 | -1.1% | $1.81 | $1.81 | $1.77 | 785,000 | |
| $1.83 | +0.03 | +1.7% | $1.79 | $1.87 | $1.775 | 563,300 | |
| $1.80 | -0.14 | -7.2% | $1.94 | $1.96 | $1.795 | 839,100 | |
| $1.94 | +0.05 | +2.6% | $1.90 | $1.95 | $1.875 | 838,600 | |
| $1.89 | +0.01 | +0.5% | $1.91 | $1.94 | $1.875 | 472,200 | |
| $1.88 | -0.005 | -0.3% | $1.88 | $1.90 | $1.84 | 399,100 | |
| $1.885 | +0.015 | +0.8% | $1.89 | $1.93 | $1.845 | 551,800 | |
| $1.87 | +0.04 | +2.2% | $1.84 | $1.89 | $1.825 | 440,200 | |
| $1.83 | -0.05 | -2.7% | $1.89 | $1.89 | $1.81 | 648,300 | |
| $1.88 | -0.01 | -0.5% | $1.91 | $1.915 | $1.85 | 378,300 | |
| $1.89 | -0.01 | -0.5% | $1.90 | $1.915 | $1.83 | 459,700 | |
| $1.90 | -0.08 | -4.0% | $1.97 | $1.97 | $1.85 | 613,500 | |
| $1.98 | +0.03 | +1.5% | $1.93 | $1.995 | $1.90 | 743,900 | |
| $1.95 | -0.01 | -0.5% | $1.96 | $1.97 | $1.91 | 827,100 | |
| $1.96 | +0.03 | +1.6% | $1.91 | $1.96 | $1.91 | 1,178,500 | |
| $1.93 | -0.01 | -0.5% | $1.98 | $2.02 | $1.92 | 665,300 | |
| $1.94 | -0.03 | -1.5% | $1.97 | $2.007 | $1.915 | 733,900 | |
| $1.97 | -0.06 | -3.0% | $2.02 | $2.02 | $1.94 | 301,800 | |
| $2.03 | +0.05 | +2.5% | $1.98 | $2.04 | $1.97 | 514,100 | |
| $1.98 | +0.02 | +1.0% | $1.99 | $2.00 | $1.94 | 589,100 | |
| $1.96 | -0.14 | -6.7% | $2.06 | $2.06 | $1.92 | 676,100 | |
| $2.10 | 0.00 | 0.0% | $2.09 | $2.149 | $2.065 | 402,400 | |
| $2.10 | -0.02 | -0.9% | $2.09 | $2.13 | $2.072 | 367,200 | |
| $2.12 | +0.02 | +1.0% | $2.08 | $2.145 | $2.061 | 323,700 | |
| $2.10 | -0.04 | -1.9% | $2.15 | $2.166 | $2.06 | 609,800 | |
| $2.14 | +0.10 | +4.9% | $2.08 | $2.155 | $2.05 | 561,300 | |
| $2.04 | -0.06 | -2.9% | $2.09 | $2.11 | $2.02 | 759,100 | |
| $2.10 | -0.13 | -5.8% | $2.22 | $2.225 | $2.10 | 507,000 | |
| $2.23 | -0.04 | -1.8% | $2.28 | $2.29 | $2.17 | 521,900 | |
| $2.27 | 0.00 | 0.0% | $2.26 | $2.32 | $2.24 | 457,600 | |
| $2.27 | +0.03 | +1.3% | $2.21 | $2.29 | $2.16 | 491,300 | |
| $2.24 | +0.085 | +3.9% | $2.19 | $2.245 | $2.185 | 417,500 | |
| $2.155 | -0.055 | -2.5% | $2.22 | $2.22 | $2.13 | 345,000 | |
| $2.21 | +0.06 | +2.8% | $2.15 | $2.26 | $2.15 | 656,600 | |
| $2.15 | -0.04 | -1.8% | $2.17 | $2.19 | $2.08 | 1,137,800 |
- Ticker
- NASDAQ:BDTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Latest deck · Dec 3, 2025
Corporate Update (December 2025)
Corporate update · 38 slides
Latest news
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Nov 12, 2026
Closed $1.47 (-3.3%) on Nov 13, 2026
Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update
Nov 10, 2026
Closed $1.60 (-14.2%) on Nov 10, 2026
Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC
Nov 9, 2026
Closed $1.60 (-14.2%) on Nov 10, 2026
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Sep 2, 2026
Closed $2.10 (-1.9%) on Sep 3, 2026
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 5, 2026
Closed $1.92 (+7.3%) on Aug 6, 2026
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
May 21, 2026
Closed $2.28 (-35.8%) on May 22, 2026
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
May 19, 2026
Closed $3.00 (+16.3%) on May 19, 2026
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
Closed $2.72 (-3.5%) on May 7, 2026
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
Apr 21, 2026
Closed $3.15 (+3.3%) on Apr 21, 2026
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Mar 16, 2026
Closed $2.23 (+1.8%) on Mar 17, 2026
Black Diamond Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 100 in all · newest Nov 12, 2026 · oldest 2020
- Decks
- 8 decks · latest Dec 3, 2025
Where Black Diamond Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BDTX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:BDTX | BOATS | United States | USD |
Valuation
Price/book 0.8× against a median of 2.4×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$10.71M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.8×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.2×
- Beta vs S&P 500
- 1.76
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Black Diamond Therapeutics, Inc. · NASDAQ:BDTX | US$75.28M | −US$10.71M | n/a | n/a | n/a | 0.8× | n/a | 0.2× | 1.76 |
| TiumBio Co., Ltd. · KRX:321550 | US$77.24M | US$60.57M | n/a | 5.4× | n/a | 2.9× | −114.1% | 0.3× | n/a |
| HLB Therapeutics Co., Ltd. · KRX:115450 | US$76.82M | US$66.93M | n/a | 1.4× | n/a | 0.7× | −28.0% | 0.0× | n/a |
| Recce Pharmaceuticals Ltd. · ASX:RCE | US$75.90M | US$81.02M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Great Novel Therapeutics Biotech & Medicals Corp. · TPEX:7427 | US$73.93M | US$52.73M | n/a | 1,442× | n/a | 3.2× | n/a | 0.0× | n/a |
| Pentixapharm Holding AG · XETR:PTP | US$73.87M | US$69.92M | n/a | 1,158× | n/a | 2.4× | n/a | 0.0× | n/a |
| Dimerix Limited · ASX:DXB | US$73.52M | US$62.98M | n/a | 21.9× | n/a | n/a | −685.3% | n/a | n/a |
| Faron Pharmaceuticals Oy · LSE:FARN | US$72.99M | US$57.36M | n/a | n/a | n/a | 5.7× | n/a | 1.5× | n/a |
| Kanaph Therapeutics Inc. · KRX:0082N0 | US$72.81M | US$39.07M | n/a | 9.3× | n/a | 2.1× | −729.8% | 0.0× | n/a |
| Cellectis S.A. · EURONEXT:ALCLS | US$72.64M | −US$9.64M | n/a | −0.2× | n/a | 1.8× | −115.4% | 2.1× | n/a |
| Eastwood Bio-Medical Canada Inc · TSXV:EBM | US$72.06M | US$72.05M | n/a | 127× | n/a | n/a | −28.5% | n/a | 0.56 |
| Median of the others | US$73.69M | US$61.78M | 15.6× | 2.4× | −114.7% | 0.0× | 0.56 |
Forecasts
5 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 10.86 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.68 · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Mark A. Velleca | Chief Executive Officer |
| Prakash Raman | CEO of InduPro, Inc. |
| Samarth Kulkarni | CEO, CRISPR Therapeutics AG |
| Brent Hatzis-Schoch | Chief Operating Officer, General Counsel |
| Erika Jones | Senior Vice President of Finance and Principal Financial & Accounting Officer |
| Ali Behbahani | Co-Head of Healthcare, NEA |
| Elizabeth Buck | Co-Founder, Chief Scientific Officer |
| Melanie Morrison | Chief Development Officer |
| Sergey Yurasov | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Mark A. Velleca | Chief Executive Officer |
| Ali Behbahani | Co-Head of Healthcare, NEA |
| Garry E. Menzel | Operating Partner, GHO Capital Partners LLP |
| Kapil Dhingra | Director |
| Prakash Raman | CEO of InduPro, Inc. |
| Samarth Kulkarni | CEO, CRISPR Therapeutics AG |
| Shannon Campbell | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | −14.3% |
| Q2 2026 | Aug 5, 2026 · After close | +7.3% |
| Q1 2026 | May 7, 2026 · Before open | −3.5% |
| Q4 2025 | Mar 18, 2026 | −3.6% |
| Q3 2025 | Nov 6, 2025 · Before open | +2.8% |
| Q2 2025 | Aug 7, 2025 · Before open | −15.2% |
| Q1 2025 | May 12, 2025 · After close | +10.3% |
| Q4 2024 | Mar 10, 2025 · Before open | −9.0% |
| Q3 2024 | Nov 5, 2024 · Before open | +8.7% |
| Q2 2024 | Aug 6, 2024 · Before open | −5.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | −2.7% |
| Q4 2023 | Mar 12, 2024 · Before open | −5.5% |
| Q3 2023 | Nov 6, 2023 · Before open | +0.5% |
| Q2 2023 | Aug 11, 2023 · Before open | −2.4% |
| Q1 2023 | May 9, 2023 · Before open | −5.2% |
| Q4 2022 | Mar 9, 2023 · Before open | −13.7% |
| Q3 2022 | Nov 8, 2022 · Before open | +3.2% |
| Q2 2022 | Aug 9, 2022 · Before open | +0.8% |
| Q1 2022 | May 11, 2022 · After close | −1.6% |
| Q4 2021 | Mar 17, 2022 · After close | +5.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (December 2025) | Corporate update | 38 slides | Dec 3, 2025 |
| Investor Presentation (March 2025) | Investor deck | 38 slides | Mar 19, 2025 |
| AACR Annual Meeting 2024 | Conference | 15 slides | Apr 5, 2024 |
| Investor Presentation (January 2024) | Investor deck | 42 slides | Jan 4, 2024 |
| Investor Presentation (April 2022) | Investor deck | 38 slides | Apr 25, 2022 |
| Investor Presentation (January 2022) | Investor deck | 39 slides | Jan 10, 2022 |
| Technical Presentation (2021) | Technical | 10 slides | 2021 |
| 32nd EORTC-NCI-AACR Virtual Symposium 2020 | Conference | 13 slides | Oct 24, 2020 |
IPO
Priced at US$19.00 a share on Jan 29, 2020.
- Price
- US$19.00 a share
- Shares offered
- 10,586,316 shares of common stock
- Offering size
- US$201.1 million
- Underwriters' option
- Up to 1,587,947 more shares
- Underwriters
- J.P. Morgan, Jefferies, Cowen, Canaccord Genuity · In the order on the cover
- Shares delivered
- On or about Feb 3, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 23, 2019 |
| Filed publicly | Jan 3, 2020 |
| Amended once | Jan 21, 2020 |
| Shares registered with an exchange | Jan 27, 2020 |
| Declared effective by the SEC | Jan 29, 2020 |
| Final prospectus, with the price | Jan 30, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jan 30, 2020 |
| EFFECT · Notice that a registration is effective | Jan 29, 2020 |
| S-1MEF · Registration of more shares for the same offering | Jan 29, 2020 |
| CERT · Exchange's certificate of listing | Jan 29, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 27, 2020 |
| CORRESP · Letter to the SEC | Jan 27, 2020 |
| CORRESP · Letter to the SEC | Jan 27, 2020 |
| CORRESP · Letter to the SEC | Jan 21, 2020 |
| S-1/A · Registration statement, amended | Jan 21, 2020 |
| CORRESP · Letter to the SEC | Jan 13, 2020 |
All 20 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Jan 10, 2020 |
| S-1 · Registration statement | Jan 3, 2020 |
| DRS/A · Draft registration statement, amended | Dec 13, 2019 |
| DRSLTR · Letter to the SEC with a draft | Oct 30, 2019 |
| DRS/A · Draft registration statement, amended | Oct 30, 2019 |
| UPLOAD · Letter from the SEC | Oct 17, 2019 |
| DRSLTR · Letter to the SEC with a draft | Oct 7, 2019 |
| DRS/A · Draft registration statement, amended | Oct 7, 2019 |
| UPLOAD · Letter from the SEC | Sep 19, 2019 |
| DRS · Draft registration statement | Aug 23, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Jan 30, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 325.0K | 343.0K | 437.0K | 3.24M | 2.22M | 600.0K | 47.0K | 44.0K | 24.0K |
| Gross profit | 69.7M | -343.0K | -437.0K | -3.24M | -2.22M | -600.0K | -47.0K | -44.0K | -24.0K |
| Research and development | 33.6M | 51.3M | 59.4M | 64.4M | 96.8M | 48.2M | 21.8M | 6.95M | 3.45M |
| Selling, general and administrative | 16.6M | 27.5M | 27.1M | 28.4M | 30.0M | 21.4M | 7.58M | 1.95M | 666.0K |
| Operating income | 12.5M | -78.8M | -86.5M | -92.8M | -126.9M | -69.6M | -29.3M | -8.90M | -4.12M |
| Depreciation and amortization | 325.0K | 343.0K | 437.0K | 508.0K | 205.0K | 52.0K | 47.0K | 44.0K | 24.0K |
| EBITDA | 12.8M | -78.4M | -86.0M | -92.3M | -126.7M | -69.5M | -29.3M | -8.86M | -4.09M |
| Interest expense | 3.91M | 0 | 1.00K | 0 | 0 | 65.0K | |||
| Income before tax | 22.4M | -69.7M | -82.6M | -91.3M | -125.3M | -67.0M | -35.3M | -8.93M | -4.60M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 59.0K |
| Net income | 22.4M | -69.7M | -82.4M | -91.2M | -125.6M | -67.3M | -35.3M | -8.93M | -4.60M |
| Earnings per share, basic | 0.39 | -1.27 | -1.88 | -2.52 | -3.47 | -2.05 | -16.99 | -4.42 | -0.64 |
| Earnings per share, diluted | 0.39 | -1.27 | -1.88 | -2.52 | -3.47 | -2.05 | -16.99 | -4.42 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 21.0M | 36.4M | 56.2M | 34.3M | 65.8M | 34.6M | 154.7M | 51.7M | 7.88M |
| Short-term investments | 107.7M | 62.1M | 75.2M | 88.5M | 144.0M | 280.5M | 0 | ||
| Current assets | 132.4M | 101.2M | 134.0M | 127.7M | 215.7M | 319.6M | 155.7M | 51.7M | 7.91M |
| Property, plant and equipment | 365.0K | 1.39M | 1.73M | 2.59M | 3.04M | 385.0K | 164.0K | 134.0K | 102.0K |
| Total assets | 143.0M | 122.6M | 158.6M | 156.3M | 247.7M | 329.7M | 158.3M | 51.8M | 8.02M |
| Accounts payable | 579.0K | 4.01M | 2.32M | 1.88M | 4.11M | 2.54M | 1.96M | 416.0K | 152.0K |
| Current liabilities | 15.7M | 20.6M | 19.6M | 15.3M | 23.6M | 14.2M | 4.86M | 2.58M | 2.23M |
| Total debt | 18.8M | 22.2M | 25.3M | 28.1M | 28.5M | 8.74M | 200.6M | 60.8M | 12.5M |
| Total liabilities | 30.8M | 39.4M | 41.8M | 40.6M | 51.8M | 21.9M | 4.88M | 6.60M | 14.7M |
| Shareholders' equity | 112.2M | 83.3M | 116.7M | 115.7M | 195.9M | 307.8M | -47.2M | -15.5M | -6.67M |
| Shares outstanding | 57.1M | 56.6M | 51.6M | 36.4M | 36.2M | 36.1M | 2.24M | 2.17M | 7.20M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 29.6M | -62.3M | -66.7M | -85.1M | -100.1M | -52.1M | -24.7M | -8.45M | -2.35M |
| Capital spending | 0 | 0 | -33.0K | -192.0K | -2.71M | -142.0K | -21.0K | -76.0K | -77.0K |
| Free cash flow | 29.6M | -62.3M | -66.8M | -85.3M | -102.9M | -52.3M | -24.7M | -8.53M | -2.43M |
| Cash from investing | -44.9M | 17.0M | 16.3M | 53.4M | 130.6M | -281.7M | -21.0K | -76.0K | -77.0K |
| Cash from financing | -146.0K | 25.5M | 71.9M | 177.0K | 729.0K | 214.9M | 127.8M | 52.3M | 9.97M |
| Share buybacks | 177.0K | 729.0K | 214.9M | 129.5M | 52.3M | 10.0M | |||
| Change in cash | -15.4M | -19.8M | 21.6M | -31.5M | 31.2M | -118.9M | 103.1M | 43.8M | 7.55M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 4 · Change in ownership | Sep 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 21, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 8, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 29, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 8-K · Current report | May 21, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 16, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 16, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 16, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 4, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 3, 2025 | Results | SEC |
| CORRESP · Letter to the SEC | Dec 1, 2025 | Other filings | SEC |
| S-3 · Registration statement | Nov 13, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 29, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 18, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 18, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 18, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 21, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 19, 2025 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Mar 6, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 6, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Oct 24, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 7, 2024 | Management or board change | SEC |
| 8-K · Current report | Sep 23, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 30, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 8, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 144 · Notice of proposed sale | Jul 31, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 26, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 11, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 10, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 9, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 28, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 27, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 26, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 21, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 20, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 20, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 14, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 13, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 12, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2024 | Meeting outcome | SEC |
| SC 13D/A · Big-stake notice, amended | May 13, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | May 9, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 24, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 12, 2024 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Apr 12, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 11, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Apr 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 12, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 11, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 15, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 18, 2024 | Management or board change | SEC |
| 8-K · Current report | Jan 4, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 13, 2023 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 9, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2023 | Results | SEC |
| 4 · Change in ownership | Oct 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 18, 2023 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2023 | Results | SEC |
| 4 · Change in ownership | Jul 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 30, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Jun 30, 2023 | Offer document | SEC |
| 4 · Change in ownership | Jun 29, 2023 | Insider trade | SEC |
| 424B5 · Prospectus | Jun 29, 2023 | Offer document | SEC |
| 4 · Change in ownership | Jun 28, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 27, 2023 | Other filings | SEC |
| 8-K · Current report | Jun 27, 2023 | Current report | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2023 | Insider trade | SEC |
| 8-K · Current report | May 16, 2023 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2023 | Results | SEC |
| ARS · Annual report to shareholders | Apr 4, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 4, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 4, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2023 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 9, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 9, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 9, 2023 | Results | SEC |
| 4 · Change in ownership | Feb 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 15, 2023 | Insider trade | SEC |
This page holds 200 of 487 filings. Open Filings
Cap table
Built by 6ix from Black Diamond Therapeutics, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 57,468,255
- Fully diluted
- 57,468,255
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 57,468,255 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 57,468,255 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Jan 29, 2020 – Jul 5, 2023 · Past |
| Ali Behbahani Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); NeueHealth Inc (Director · Since at least Oct 2, 2025); Korro Bio, Inc. (Director · Since at least Nov 3, 2023); Arcellx Inc (Director · Since at least Feb 3, 2022); Monte Rosa Therapeutics, Inc. (Director · Since at least Jun 23, 2021); Nkarta, Inc. (Director · Since at least Jul 9, 2020); Adaptimmune Therapeutics PLC (Director · Since at least Jul 2, 2019); CRISPR Therapeutics AG (Director · Since at least Jun 11, 2019); Minerva Surgical, Inc. (Director · Oct 21, 2021 – Jun 10, 2022 · Past); CVRx, Inc. (Director · Jun 29, 2021 – Jun 4, 2024 · Past); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 3, 2023 · Past) | Director · Since at least Jan 29, 2020 |
| Garry E. Menzel Other companies: Adaptimmune Therapeutics PLC (Non-Executive Director · Since at least Jun 1, 2023); Stoke Therapeutics, Inc. (Director · Since at least Aug 13, 2020); Tcr2 Therapeutics Inc (President and CEO, Director · Feb 13, 2019 – Jun 1, 2023 · Past); DaVita Inc. (Senior Vice President, Finance · Sep 9, 2013 – Sep 9, 2013 · Past); Regulus Therapeutics Inc (COO & Executive VP, Finance · Oct 4, 2012 – Dec 11, 2012 · Past) | Operating Partner, GHO Capital Partners LLP · Since at least Jan 29, 2020 |
| Kapil Dhingra Other companies: LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); CARGO Therapeutics, Inc. (Director · Since at least Apr 15, 2024); Replimune Group, Inc. (Director · Since at least Jul 19, 2018); Five Prime Therapeutics Inc (Director · Dec 2, 2015 – Apr 16, 2021 · Past) | Director · Since at least Jan 19, 2021 |
| Samarth Kulkarni Other companies: Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Centessa Pharmaceuticals PLC (Director · Since at least May 27, 2021); CRISPR Therapeutics AG (Chief Executive Officer and Chairman of the Board · Since at least Oct 18, 2016); Repare Therapeutics Inc (Director · Jun 18, 2020 – Jun 17, 2024 · Past) | CEO, CRISPR Therapeutics AG · Since at least Jan 29, 2020 |
| Rachel Humphrey Other companies: Pyxis Oncology, Inc. (Director · Since at least Aug 11, 2022); Xilio Therapeutics, Inc. (Director · Oct 21, 2021 – Oct 21, 2021 · Past) | Chief Medical Officer · Feb 17, 2021 – Feb 17, 2021 · Past |
| Sergey Yurasov Other companies: Nuvation Bio Inc. (Chief Medical Officer · Feb 10, 2021 – Feb 10, 2021 · Past); Immune Design Corp (Sr. VP, Clinic. Devel. & CMO · Oct 1, 2016 – Apr 2, 2019 · Past) | CHIEF MEDICAL OFFICER · Since at least Jun 10, 2022 |
| David M Epstein Other companies: Gyre Therapeutics, Inc. (Director · Since at least Aug 6, 2024) | SEE REMARKS, Director · Jan 29, 2020 – Jun 27, 2023 · Past |
| Mark A. Velleca Other companies: G1 Therapeutics Inc (Director · May 16, 2017 – Aug 8, 2023 · Past) | Chief Executive Officer · Since at least Aug 9, 2021 |
| Prakash Raman Other companies: Olema Pharmaceuticals, Inc. (Director · Since at least Apr 28, 2026) | CEO of InduPro, Inc. · Since at least Apr 10, 2024 |
All 17 people
| Person | Seat |
|---|---|
| Brent Hatzis-Schoch | Chief Operating Officer, General Counsel · Since at least Nov 5, 2026 |
| Elizabeth Buck | Co-Founder, Chief Scientific Officer · Since at least Sep 15, 2021 |
| Elizabeth L. Montgomery | Chief People Officer · Jan 28, 2026 – Nov 5, 2026 · Past |
| Erika Jones | Senior Vice President of Finance and Principal Financial & Accounting Officer · Since at least Nov 18, 2021 |
| Fang Ni | SEE REMARKS · Nov 18, 2021 – Feb 14, 2024 · Past |
| Melanie Morrison | Chief Development Officer · Since at least Nov 5, 2026 |
| Shannon Campbell | Director · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Black Diamond Therapeutics, Inc.